The Searle Co. Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PK0061701014
PKR
89.83
-3.06 (-3.29%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About The Searle Co. Ltd. stock-summary
stock-summary
The Searle Co. Ltd.
Pharmaceuticals & Biotechnology
The Searle Company Limited is a holding company, which is principally engaged in the manufacture of pharmaceutical products and other consumer products. In addition, the Company is engaged in sale of food and consumer products, and manufacture of pharmaceutical products for other companies. The Company operates through three segments: Pharma, Consumer and Investment property. The Company's geographical segments include Pakistan, South Asia, East Africa, South-East Asia and Middle East. The Company's portfolio includes three divisions: Pharma, Consumer Health and Nutrition. Its products include Selanz SR, Levoxin, Lomotil, Xaroban, Vitrum, Rhulef, Canderel, Peditral, Ezium, Hydryllin, Xadine, Zenbar, Extor, Adronil, Nuberol/Nuberol Forte and Byscard. The Company has pharmaceutical range across therapeutic areas, such as cardiovascular, respiratory care, gastroenterology, pain management, orthocare, neuropsychiatry, probiotics, antibiotics and nutritional care.
Company Coordinates stock-summary
Company Details
1st Floor, N.I.C. Building, Abbasi Shaheed Road KARACHI None : 75530
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Adnan Asdar Ali
Chairman of the Board
Mr. Syed Ahmed
Chief Executive Officer, Director
Mr. Zubair Razzaq Palwala
Company Secretary, Executive Director
Mr. Asad Abdulla
Director
Ms. Shaista Rehman
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
7,001 Million
(Quarterly Results - Mar 2025)
Net Profit:
161 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PKR 66,398 Million (Large Cap)

stock-summary
P/E

78.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.22

stock-summary
Return on Equity

4.31%

stock-summary
Price to Book

2.01